00085472can143362-sup-141043_2_supp_3103672_nt3bl6.pptx (2.56 MB)
Supplementary Table and Supplementary Figures 1 through 6 from Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
figure
posted on 2023-03-30, 23:45 authored by Kristin J. Lastwika, Willie Wilson, Qing Kay Li, Jeffrey Norris, Haiying Xu, Sharon R. Ghazarian, Hiroshi Kitagawa, Shigeru Kawabata, Janis M. Taube, Sheng Yao, Linda N. Liu, Joell J. Gills, Phillip A. DennisSupplemental Table 1. Clinical and pathologic characteristics of patients included in tissue microarrays Supplementary Figure 1. B7-H4 expression is low in human and mouse lung cancer cell lines in vitro Supplementary Figure 2. B7-H1 expression does not change with MAPK or proliferation inhibition Supplementary Figure 3. Scoring of PD-L1 and pS6 staining in lung adenocarcinoma and squamous cell carcinoma TMAs Supplementary Figure 4. Co-expression of pS6 and PD-L1 staining in TMAs Supplemental Figure 5. The combination of rapamycin and anti-PD-1 antibody decreases KRAS-driven lung tumor growth Supplementary Figure 6. The combination of rapamycin and αPD-1 blockade decreases NNK-derived syngeneic lung tumor growth.